Figure 1. Effect of the WT and K⁴⁰⁹A rHsp65 treatment on SLE.

Effect of the WT rHsp65 administration on survival time [A]. Female [NZBxNZW]F₁ mice were treated or not [▪] with a single dose [2.5 µg] of WT [▴] or K⁴⁰⁹A [○]rHsp65 at 45 days of age. Age-dependence effect of the WT rHsp65 treatment on MST [B]. Dose-dependence of WT rHsp65 on F₁ MST [C]. MST [Mean survival time; days]; VE [environmental variance]; Ascite: development of ascite [+++: high incidence; -: not development]. Untreated group has been the reference group for log-rank analysis; ***p<0.001. Results are representative of 2 independent experiments.